Bevacizumab 100 mg/4 mL, 400 mg/16 mL Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 100 mg/4 mL, 400 mg/16 mL

Reference Brands: Avastin (USA)

Category: Oncology Cancer Care

Bevacizumab is a recombinant humanized monoclonal antibody that targets vascular endothelial growth factor (VEGF), a protein responsible for the growth of new blood vessels. By blocking VEGF, it helps prevent the formation of blood vessels that feed tumors, thereby slowing their growth.

Product Description:

Bevacizumab is a monoclonal antibody and anti-angiogenesis agent that works by binding to vascular endothelial growth factor (VEGF), helping to prevent the formation of new blood vessels that tumors need to grow. It is used to treat a variety of cancers, including cervical cancer, colorectal cancer, non-small cell lung cancer, renal cell carcinoma, glioblastoma, ovarian epithelial cancer, fallopian tube cancer, primary peritoneal cancer, and hepatocellular carcinoma.

Bevacizumab is available under multiple brand names, including Avastin®, Alymsys®, Mvasi®, and Zirabev®, and can be used alone or in combination with other anticancer therapies depending on the indication. By inhibiting tumor angiogenesis, bevacizumab slows cancer progression and helps improve treatment outcomes.

The drug is also under investigation for use in other cancer types, reflecting its broad potential as a targeted therapy. Administered as a sterile intravenous infusion, bevacizumab requires careful monitoring for adverse effects such as hypertension, bleeding, and impaired wound healing. Its targeted mechanism and multiple approved indications make it a cornerstone in modern oncology therapy.